SciSparc Ltd. and Clearmind Medicine Inc. Collaboration

0
46


TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical firm specializing in the event of therapies to deal with problems of the central nervous system, at present introduced that Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), has filed a provisional patent software associated to metabolic syndromes together with weight problems, concerning the Company’s collaboration with Clearmind.

The patent software is the third of the collaboration, every referring to the proprietary mixture of SciSparc’s Palmitoylethanolamide (PEA), the lively ingredient of its proprietary CannAmide™ (for treating weight problems and its associated metabolic problems) and Clearmind’s MEAI, a novel proprietary psychedelic therapy for varied addictions and based mostly on analysis on the Hebrew University.

“Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind’s. Obesity, over- weightness and binge eating are among the biggest health concerns of the past decade and are related to addictive behavior, and yet treating options available in the market are very limited,” commented Oz Adler, SciSparc’s Chief Executive Officer. “We believe that combining MEAI with SciSparc’s CannAmide™ may create a great opportunity in treating these conditions.”

About SciSparc Ltd. (NASDAQ: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical firm led by an skilled staff of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of applied sciences and property based mostly on cannabinoid prescription drugs. With this focus, the Company is presently engaged within the following drug growth applications based mostly on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the therapy of Tourette Syndrome, for the therapy of Alzheimer’s illness and agitation; SCI-160 for the therapy of ache; and SCI-210 for the therapy of autism spectrum dysfunction and standing epilepticus.

See also  High-Quality Health Care at Low Costs Has Increased the Influx of Patients to Monterrey Mexico

Forward-Looking Statements:

This press launch accommodates forward-looking statements throughout the which means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and different Federal securities legal guidelines. For instance, SciSparc is utilizing forward-looking statements when it discusses the power of the mix of MEAI with SciSparc’s CannAmide™ to efficiently deal with weight problems and metabolic situations. Because such statements cope with future occasions and are based mostly on SciSparc’s present expectations, they’re topic to numerous dangers and uncertainties and precise outcomes, efficiency or achievements of SciSparc might differ materially from these described in or implied by the statements on this press launch. The forward- trying statements contained or implied on this press launch are topic to different dangers and uncertainties, together with these mentioned underneath the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2022, and in subsequent filings with the SEC. Except as in any other case required by regulation, SciSparc disclaims any intention or obligation to replace or revise any forward-looking statements, which communicate solely as of the date they have been made, whether or not on account of new info, future occasions or circumstances or in any other case.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here